Two Radiation Dose Schedules of SBRT to Lung Metastases < 5cm in Dimension
Withdrawn before enrolling · Phase 2
Conditions studied: Neoplasm Metastasis, Cancer, Radiation Therapy Complication
In brief
30 Gy single fraction of SBRT for lung metastases will result in comparable oncologic outcomes to 18Gy in three fractions (or dosing to a BED \</-100Gy at the discretion of the radiation oncologist) with respect to disease control and toxicity.
Key facts
- Study ID
- NCT03029416
- Run by
- Ronald McGarry
- People needed
- 0
- Starts
- 2017-10-26
- Expected to finish
- 2018-08-09
- Last updated by the study team
- 2018-10-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histological confirmation of malignant carcinoma/sarcoma (any site) with metastasis to lung.
- Patients must not be eligible for therapy with curative intent (i.e. surgery, radiation, etc).
- Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension
- Age ≥18 years
- ECOG performance status >/= 2 (Karnofsky≥60%)).
- Ability to understand and the willingness to sign a written informed consent document.
You may not qualify if…
- Patients with more than >/=3 metastatic lung lesions or any one lesion greater than 5 cm. and/or extensive metastatic disease outside the chest.
- Patients who are receiving any other investigational agents.
- Patients with active systemic, pulmonary, or pericardial infection.
- Pregnant or lactating women
- Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
- Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Chemotherapy concurrent with SBRT is not allowed
Where it is running
- University of Kentucky — Lexington, Kentucky, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.